Clinical Trial Update: SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SY-005 (Recombinant Human Annexin A5) in patients with sepsis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• SY-005 (Recombinant Human Annexin A5)

Snippet

Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Conditions: Sepsis | Phase 2 | Status: UNKNOWN